Corvus Pharmaceuticals (CRVS)

• Market cap: $679M
• 1 day: 2.02%
• 5 days: 10.99%
• 1 month: 21.69%
• 3 months: 70.86%
• 6 months: 151.1%
• Year to date: 67.4%
• 1 year: 8.99%
• 5 years: 121.71%
• 10 years: -36.21%
• Sector: Healthcare
• Industry: Biotechnology

About: Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).

Employees: 31